Plörer S, Gerstenbrand F, Lehmann H E, Saltuari L, Stralkowski E
Psychiatr Neurol Med Psychol (Leipz). 1985 Nov;37(11):635-42.
A clear difference between active drug and placebo is not always found when using the ascending and descending thresholds of the critical flicker fusion test (CFF). We selected a test requiring attention and concentration and performed again the CFF after this 6-minute concentration-test (reactive CFF). This reactive CFF was then used in a double-blind study in 30 ambulant patients with cerebro-vascular arteriosclerosis treated for 8 weeks with 80 mg/day cervoxan or placebo. After the treatment period the reaction of the CFF after the 6-minute concentration-test demonstrated a significantly more frequent improvement of the vigilance in the Cervoxan group compared to the placebo group.
在使用临界闪烁融合试验（CFF）的升、降阈值时，并非总能发现活性药物与安慰剂之间存在明显差异。我们选择了一项需要注意力和专注力的测试，并在这项6分钟的专注力测试后再次进行CFF（反应性CFF）。然后，将这种反应性CFF用于一项双盲研究，该研究纳入了30名门诊脑血管动脉硬化患者，他们被随机分为两组，一组每天服用80毫克塞尔沃赞，另一组服用安慰剂，为期8周。治疗期结束后，6分钟专注力测试后的CFF反应显示，与安慰剂组相比，塞尔沃赞组的警觉性改善更为频繁，差异具有统计学意义。
